KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in TaxesDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and Equipment
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Gsk (GSK) over the last 17 years, with Q4 2025 value amounting to $3.6 billion.

  • Gsk's Cash from Operations rose 37.78% to $3.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $11.9 billion, marking a year-over-year increase of 2898.9%. This contributed to the annual value of $11.8 billion for FY2025, which is 1736.47% up from last year.
  • As of Q4 2025, Gsk's Cash from Operations stood at $3.6 billion, which was up 37.78% from $3.4 billion recorded in Q3 2025.
  • Gsk's Cash from Operations' 5-year high stood at $3.7 billion during Q1 2022, with a 5-year trough of $348.9 million in Q1 2023.
  • Its 5-year average for Cash from Operations is $2.3 billion, with a median of $2.3 billion in 2021.
  • In the last 5 years, Gsk's Cash from Operations soared by 45162.68% in 2022 and then plummeted by 9056.33% in 2023.
  • Over the past 5 years, Gsk's Cash from Operations (Quarter) stood at $2.2 billion in 2021, then surged by 31.13% to $2.9 billion in 2022, then dropped by 17.5% to $2.4 billion in 2023, then surged by 50.54% to $3.6 billion in 2024, then increased by 0.38% to $3.6 billion in 2025.
  • Its last three reported values are $3.6 billion in Q4 2025, $3.4 billion for Q3 2025, and $3.2 billion during Q2 2025.